{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.4","value":"-17.1"},{"groupId":"OG001","spread":"54.0","value":"-6.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"493"}],"units":"Participants"}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.7","value":"-15.9"},{"groupId":"OG001","spread":"58.4","value":"-1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"412"},{"groupId":"OG001","value":"409"}],"units":"Participants"}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"78.9","value":"-16.8"},{"groupId":"OG001","spread":"73.7","value":"5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"284"}],"units":"Participants"}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.3","value":"-8.1"},{"groupId":"OG001","spread":"66.2","value":"1.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.8","value":"-11.1"},{"groupId":"OG001","spread":"68.3","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"271"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"66.5","value":"-4.6"},{"groupId":"OG001","spread":"60.3","value":"-2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"257"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"493"}],"units":"Participants"}],"description":"Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","dispersionType":"Standard Deviation","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEAN","populationDescription":"The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.","reportingStatus":"POSTED","timeFrame":"Days 1, 3, 5, 8, 11, 15 and 29","title":"Change From Baseline in Glucose","type":"SECONDARY","unitOfMeasure":"mg/dL"}